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Abstract
Background: To evaluate differences in the proportion of uterine fibroid (UF) treatments that are uterine-
sparing between Black women and White women and identify factors that could explain disparities.
Methods: Women at age 18–54 years who were enrolled from 10 clinical sites in the United States into the
Comparing Options for Management: Patient-Centered Results for UFs (COMPARE-UF) treatment registry
completed questionnaires before their UF procedure. UF symptoms and quality of life were assessed by ques-
tionnaires. Details on UF imaging and treatment (hysterectomy, myomectomy, or uterine artery embolization
[UAE]) were collected from each patient’s medical record. Random-effects logistic regression was used to assess
the association between race and the odds of having a uterine-sparing procedure versus hysterectomy. Subgroup
analyses compared each uterine-sparing procedure with hysterectomy.
Results: In this cohort of 1141 White women and 1196 Black women, Black women tended to be younger
(median 41.0 vs. 42.0 years) and report worse symptoms, pain, and function on every scale compared with
White women. Black women were more likely to have had a prior UF treatment compared with White women
(22.8% vs. 14.6%). White women had more hysterectomies (43.6% vs. 32.2%) and myomectomies (50.9% vs.
50.2%) versus Black women. Black women had more UAEs (15.1% vs. 4.7%) than White women. After
adjusting for clinical site and other variables, Black women had greater odds than White women of having a
myomectomy (odds ratio [OR] = 2.41, 95% confidence interval [CI] = 1.63–3.56) or a UAE versus hysterec-
tomy (OR = 4.24, 95% CI = 2.41–7.46).
Conclusion: In these participants, Black women were more likely to schedule a uterine-sparing UF treatment
and a nonsurgical UF treatment than their White counterparts; this may not be true for all women. Longer
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comparative effectiveness studies are needed to inform women about the durability of UF treatments. Greater
understanding of factors influencing treatment selection is needed as are studies that include women without
access to tertiary care centers. Clinical Trial Registration: Clinicaltrials.gov, NCT02260752 (enrollment start:
November 2015).
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Introduction
By menopause, most women will have developed uterineleiomyomas (fibroids).1 Symptomatic uterine fibroids
(UFs) can cause heavy menstrual bleeding, pelvic pain and
pressure, dyspareunia, and a bulky abdominal appearance.2
UF can also adversely affect fertility and birth outcomes,
although these data are limited.3 Despite the large public
health burden of UF in the United States, little is known about
UF natural history or pathogenesis owing to a lack of lon-
gitudinal studies with imaging to confirm UF status. How-
ever, it is well accepted that the strongest risk factor for
having UF is being of Black race.4 Other suspected risk
factors include increasing age up to time of menopause and
greater time since last giving birth.4 Three-quarters of the UF
treatments in the United States are hysterectomies; however,
uterine-sparing procedures are becoming more common as
their clinical availability has increased.4 Common uterine-
sparing procedures include myomectomy (fibroid removal),
uterine artery embolization (UAE), and endometrial ablation
(EA). Those who have these uterine-sparing treatments,
however, may require additional UF treatment over time for
persistent symptoms or recurrent or new UF.
Black women are more likely than White women to de-
velop UF, with more than 80% of Black women and nearly
70% of White women having ultrasound-based evidence of
UF by menopause.1 Black women also tend to have a greater
number and larger size UF at the time of diagnosis, typically
diagnosed at younger ages relative to White women.5 The
etiology of these racial disparities is unknown. Reasons for
this may include greater provider vigilance for identification
and treatment in Black women because of the higher preva-
lence. As a result, Black women may find themselves seeking
a UF treatment at younger ages than their White counterparts.
Stewart et al. have previously reported that among women
with symptomatic UF, Black women are more likely than
White women to report a preference for uterine-sparing fi-
broid treatments.6
Using the national UF treatment registry, Comparing Op-
tions for Management: Patient-Centered Results for UFs
(COMPARE-UF), we evaluated the extent to which the
proportion of UF treatments that were uterine-sparing dif-
fered between Black women and White women.7,8 We also
investigated potential reasons for differences between Black
and White women’s choices of procedural intervention.
Methods
The COMPARE-UF registry is under the direction of the
Duke Clinical Research Institute, which served as the data-
coordinating center for enrollment and follow-up. Clinical
sites for this multisite registry across the United States are:
Brigham and Women’s Hospital, Henry Ford Health Sys-
tem, INOVA Health System, the Mayo Clinic Network, the
University of California Fibroid Network, the University of
Michigan, the University of Mississippi Medical Center,
and the University of North Carolina at Chapel Hill. Ad-
ditional participants who planned to have a UAE were re-
cruited from two specialty clinics at the Atlanta Fibroid
Center and Georgetown University. IRB approval was ob-
tained. All participants provided informed consent.7
In brief, women scheduled for an UF treatment at any of
these sites were invited to complete a baseline survey on
their health and quality of life, including the disease-specific
validated Uterine Fibroid Symptom and Quality of Life
(UFS-QOL) instrument,9–11 the EuroQOL 5-dimension with
visual analog scale for overall wellness,12 a financial toxicity
questionnaire,13 and the Patient Health Questionnaire-214
to screen for depression. Women self-reported their race.
Women also answered questions about their reproductive
health history, demographic characteristics including their
insurance type, and any prior UF treatments. Medical chart
review, performed by a centralized team of credentialed
Registered Health Information Technicians at Henry Ford
Health System, was conducted for each participant’s base-
line treatment. UF characteristics (estimated total UF vol-
ume, estimated uterine volume, and number of UF) based on
pretreatment imaging were taken from the medical chart as
were details of the treatment that was performed. Women
who were 18–54 years of age at the time of UF treatment
were recruited into the study. Although the study partici-
pants were of varying races and ethnicities, there were suf-
ficient numbers of Black and White women to assess racial
differences between these groups. Women were not ex-
cluded based on reported desire for future fertility. Black and
White women who had either an UAE, a hysterectomy, or a
myomectomy by any approach were included in these ana-
lyses. UAE and myomectomy were classified as uterine-
sparing procedures.
Participants whose planned treatment was an EA or MRI-
guided focused ultrasound (MRgFUS) were excluded from
the main analyses as these procedures were only available at a
minority of the recruitment sites. There were 193 EAs per-
formed (56% for Black women) and 166 (86.0%) were per-
formed at Henry Ford Health System, 8 were performed at the
University of Mississippi, 3 sites performed none and no
other site performed more than 5. There were 19 MRgFUS
performed—18 at the Mayo Clinic and one at Henry Ford
Health System and 79% were performed for White women.
We have included a Appendix Table A1 in which these two
procedures were added to the final models for purposes of
sensitivity analyses. Women who were using medical
management for their UF were not included in these ana-
lyses. Choosing between either initiating/continuing medical
management or having a procedural intervention like the
women in these analyses is a different decision-making process
compared with selecting a specific procedure.
Variables considered as potential confounders were those
we have previously used in our analyses.15,16 These vari-
ables include age, insurance type (public, private, or mili-
tary), financial toxicity (rather than income and education),
time since being diagnosed with UF, body mass index
(BMI) (continuous kg/m2), current use of birth control (any
birth control pill, patch, ring, implant, intrauterine device,
or injectable), whether the participant had any prior pro-
cedures for UF treatment, discomfort during intercourse,
whether the participant’s menstrual periods were ‘‘regular’’ or
‘‘predictable,’’ frequent urination, previous number of preg-
nancies, current marijuana use, calculated total fibroid volume,
calculated uterine volume, and number of fibroids identified.
Indicator variables were also created for self-report of each of
the following health conditions (comorbidities): high blood
pressure, diabetes, asthma, thyroid problems, and blood clots in
the legs or lungs. Self-report (yes/no) of the following were also
included in the analyses: having menstrual periods that lasted
7 or more days, heavy bleeding during periods, and bleeding
between periods.
Counts and percentages, as well as medians with inter-
quartile ranges, were used to describe the data. To compare
factors between race groups, we used Pearson chi-square tests
for categorical variables and chi-square rank-based group
means score test statistics for continuous variables. We then
used random-effects logistic regression to sequentially ad-
just for patient-level demographic and health variables, and
socioeconomic status (SES) represented by the financial
toxicity score, as well as clinical site. We then tested the
significance of the adjusted odds ratio (OR) in the random-
effects model. The significance test for the variance com-
ponent of the site random effects helps assess whether
clinical site is an important driving factor for differences in
procedure rates. ORs and 95% confidence intervals (CIs)
were generated to assess the association between race and
the odds of having a uterine-sparing procedure versus a
hysterectomy. Subgroup analyses were then performed to
specifically consider UAE versus hysterectomy, and myo-
mectomy versus hysterectomy.
Results
The cohort for this analysis comprised 1141 White women
and 1196 Black women. Baseline patient characteristics are
presented by race group in Appendix Table A2. In brief, the
groups significantly differed statistically for every charac-
teristic examined, including age, BMI, symptoms, and UFS-
QOL, except the visual analog score for wellness, which was
75.0 for both groups. Black women tended to be younger
(median age 41.0 vs. 42.0 years overall) and to report worse
symptoms, pain, and function on every scale compared with
White women. Black women were also more likely to have
had a previous procedure for UF treatment compared with
White women (22.8% vs. 14.6%).
Tables 1 and 2 provide the proportions of uterine-sparing
procedures planned by site and by treatment separately for
White women and Black women. Except at the University of
Mississippi Medical Center, White women had lower per-
centages of uterine-sparing treatments compared with Black
women. Overall, White women had more hysterectomies
(43.6% vs. 32.2%) and myomectomies (50.9% vs. 50.2%)
than Black women, and Black women had more UAEs
(17.6% vs. 5.5%) (Table 2).
Baseline characteristics are compared between the White
women and Black women by planned procedure in Table 3
(hysterectomy), Table 4 (myomectomy), and Table 5 (UAE).
Regardless of the planned procedure, Black women tended to
be younger and have larger BMIs. For women who plan-
ned to have a hysterectomy, Black women tended to have
more UF and greater UF volume, but this was not true for
women who planned to have an UAE. Black women who
planned a myomectomy tended to have more UF but not
greater UF volume. Among those who planned a hyster-
ectomy or myomectomy, Black women were also more
likely to have had a prior UF treatment; however, this was
not true for women who planned UAE.
Black women were more likely to report having menses
for at least 7 days compared with White women regardless
of the planned treatment. Among women who planned a
hysterectomy or myomectomy, Black women were also
more likely to have reported pelvic pain requiring medi-
cation. Black women planning a myomectomy were more
likely than White women planning a myomectomy to have
reported heavy menses.
Table 1. Proportions of Uterine-Sparing




72/92 (78.3) 47/51 (92.2)
INOVA Health System 27/90 (30.0) 53/95 (55.8)
Henry Ford Health System 47/88 (53.4) 193/246 (78.5)
Mayo Clinic Network 100/257 (38.9) 21/26 (80.8)
University of Michigan 37/70 (52.9) 25/42 (59.5)
University of California
Fibroid Network
201/246 (81.7) 74/86 (86.1)
University of Mississippi
Medical Center
18/33 (54.6) 86/203 (42.4)
University of North
Carolina at Chapel Hill
73/149 (48.9) 211/319 (66.1)
Atlanta Fibroid Centera 4/4 (100) 31/31 (100)
Georgetown Universitya 4/4 (100) 12/12 (100)
Data shown are number of women with uterine-sparing UF
treatment/all women who had a UF treatment (%).
aOnly UAE patients were recruited from these sites.
UAE, uterine artery embolization; UF, uterine fibroid.






Hysterectomy 450 (43.6) 358 (32.2)
Uterine-sparing
procedure
583 (56.4) 753 (67.8)
Myomectomy 526 (50.9) 557 (50.2)
UAE 57 (5.5) 196 (17.6)
Data are given as n (%).
Chi-square test comparing the rate of the procedure versus
hysterectomy between races, p < 0.05.
Table 3. Baseline Characteristics of Women With a Planned Hysterectomy
Characteristic White (N = 450) Black (N = 358) pa
Age (years) 46.0 (42.0, 49.0) 44.0 (41.0, 47.0) <0.05
Insurance <0.05
Private 404 (89.8) 253 (70.7)
Active military 2 (0.4) 2 (0.6)
Other 44 (9.8) 103 (28.8)
BMI (kg/m2) 27.7 (24.2, 33.0) 33.4 (28.7, 39.1) <0.05
Financial toxicity (lower score = worse status) 30.0 (23.0, 36.0) 24.0 (15.0, 31.0) <0.05
Duration of symptoms (years) 3.0 (1.0, 8.0) 5.0 (2.0, 12.0) <0.05
Any bleeding symptoms 375 (83.9) 306 (85.7) 0.48
Menses ‡7 days 254 (56.8) 229 (64.1) 0.04
Heavy menses 344 (77.0) 284 (79.6) 0.38
Bleeding between periods 232 (51.9) 191 (53.5) 0.65
Frequent urination 263 (58.8) 218 (61.1) 0.52
Discomfort during intercourse 193 (43.2) 174 (48.7) 0.12
Pelvic pain requiring meds 209 (46.8) 201 (56.3) <0.05
Pelvic pain not during periods <0.05
Pelvic pain during periods 66 (14.8) 48 (13.4)
No pelvic pain 241 (53.9) 160 (44.8)
Current contraception 313 (69.6) 224 (62.6) <0.05
Previous medical condition (high blood pressure,
diabetes, asthma, thyroid problems, blood clots in legs)
224 (50.6) 217 (61.6) <0.05
Marijuana 27 (6.1) 27 (7.7) 0.11
Any prior UF treatment 82 (18.4) 83 (23.5) 0.08
Regular, predictable menses 263 (59.2) 168 (48.1) <0.05
Number of previous pregnancies <0.05
0 120 (27.0) 53 (15.1)
1 62 (13.9) 44 (12.5)
2 98 (22.0) 60 (17.0)
3 81 (18.2) 63 (17.9)
4 38 (8.5) 63 (17.9)
5 23 (5.2) 30 (8.5)
6 11 (2.5) 16 (4.5)
>6 12 (2.7) 23 (6.5)
Total UF volume (cm3) 123.2 (28.7, 281.9) 139.7 (43.1, 328.9) 0.05
Uterine volume (cm3) 325.6 (177.1, 601.0) 550.7 (272.6, 1037.5) <0.05
Number of UFs measured 2.0 (1.0, 3.0) 3.0 (1.0, 4.0) <0.05
Concernb 40.0 (20.0, 60.0) 25.0 (10.0, 45.0) <0.05
Activitiesb 46.4 (28.6, 71.4) 35.7 (17.9, 60.7) <0.05
Energy/moodb 46.4 (28.6, 64.3) 35.7 (16.2, 57.3) <0.05
Controlb 50.0 (34.4, 69.4) 40.0 (20.0, 65.0) <0.05
Self-consciousb 41.7 (16.7, 66.7) 33.3 (8.3, 58.3) <0.05
Sexual functionb 50.0 (25.0, 75.0) 37.5 (12.5, 62.5) <0.05
Total—sum of 6 subscale scores aboveb 44.8 (30.0, 62.9) 36.2 (18.1, 54.3) <0.05
Symptom severity (lower score indicates
more positive health status)
59.4 (43.8, 75.0) 68.8 (50.0, 84.4) <0.05
Mobility <0.05
I have no problems in walking about 360 (80.4) 232 (65.7)
I have some problems in walking about 56 (12.5) 64 (18.1)
I have moderate problems in walking about 26 (5.8) 42 (11.9)
I have severe problems in walking about 6 (1.3) 14 (4.0)
I am confined to bed 0 (0.0) 1 (0.3)
Self-care 0.06
I have no problems washing or dressing myself 423 (94.6) 321 (90.4)
I have slight problems washing or dressing myself 17 (3.8) 19 (5.4)
I have moderate problems washing or dressing myself 6 (1.3) 11 (3.1)
I have severe problems washing or dressing myself 0 (0.0) 3 (0.8)
I am unable to wash or dress myself 1 (0.2) 1 (0.3)
Usual activities 0.15
I have no problems doing my usual activities 282 (62.8) 204 (57.6)
I have slight problems doing my usual activities 94 (20.9) 76 (21.5)
I have moderate problems doing my usual activities 56 (12.5) 47 (13.3)
I have severe problems doing my usual activities 14 (3.1) 20 (5.6)
I am unable to perform my usual activities 3 (0.7) 7 (2.0)
(continued)
In the adjusted analyses, the site-level variances were sta-
tistically significantly different from 0 in all models (Table 6),
indicating that site was associated with the treatment received.
After adjusting for UF characteristics, clinical site, demo-
graphics, health, and other variables, Black women had greater
odds than White women of having a myomectomy versus
hysterectomy (OR = 2.41, 95% CI = 1.63–3.56) or a UAE
versus hysterectomy (OR = 4.24, 95% CI = 2.41–7.46) (Table 6).
The sensitivity analyses including EA and MRgFUS among
the uterine-sparing procedures yielded similar results to the
primary analysis. The CIs of both analyses largely overlap
and the point estimates have similar direction and magnitude
(Appendix Table A2).
Discussion
In this analysis from a large multisite U.S. registry of
women who planned treatment for their UF, Black women
were more likely than their White counterparts to have ei-
ther a myomectomy or UAE compared with hysterectomy
after adjustments for UF characteristics, symptoms, pre-
vious UF treatment, and financial toxicity associated with
the treatment. Furthermore, these data show that Black
women were more likely to schedule a nonsurgical treat-
ment (UAE) compared with White women. These results
align with the work of Stewart et al. showing that Black
women with symptomatic UF reported a preference for
uterine-sparing UF treatments.6 These findings point to the
importance of two high-priority research questions in the
field of UF.
First, the reasons why women, and especially Black wo-
men, may seek uterine sparing treatment options is unknown
and likely multifactorial. It may reflect distrust as a result of
historic racial inequities in forced sterilization and hyster-
ectomy.6,17,18 Choice of nonsurgical alternatives is also likely
influenced by more rapid recovery than with a hysterecto-
my16 and by the patient’s inability to take extended time off
from work or need to manage child or elder care responsi-
bilities. A woman’s decision to keep her uterus may reflect
her desire to maintain the possibility of childbearing, regardless
of her actual fertility. This may be particularly true for the
Black women who tended to be younger than the White
women having an UF procedure. Among patients who un-
derwent hysterectomy with or without oophorectomy, Far-
quhar et al. found that even 3 years after surgery, women
regretted the loss of their fertility.19 Similarly, Leppert et al.
reported that women who desired more children before
hysterectomy tended to report higher levels of depression,
anger, anxiety, and pelvic pain compared with women
without this desire at 12–24 months after surgery.20 Finally,
for some women, the uterus is essential for ‘‘feminine’’
identity. Based on focus groups and personal interviews
with African American women, 70% of whom had a hys-
terectomy, Augustus reported a general belief that women
were no longer ‘‘whole’’ women after hysterectomy.21 This
belief was also echoed in two recent focus group studies of
both Black and White women who had undergone hyster-
ectomy in Michigan and Alabama; these studies found that
because of this belief, some women undergoing hysterec-
tomy were afraid to share information about their surgery
with others.22,23
The second research question introduced by this prefer-
ence for uterine-sparing treatments, and often mul-
tiple sequential uterine-sparing treatments, is that Black
women are at increased risk of future retreatment for re-
current and new fibroid symptoms. Stimulated by ovarian
hormones, the risk of developing UF continues to meno-
pause and prior research has shown that Black women do
not have diminished growth as they reach this threshold
as do White women.24,25 Understanding the individual
clinical characteristics such as age, race/ethnicity, and
baseline UF characteristics, which are predictors of suc-
cess are critical to provide precision medicine ap-
proaches to treatment of UF. Because Black women are
disproportionally affected by UF,8 the lack of understand-
ing of predictors of subsequent treatment becomes a further
Table 3. (Continued)
Characteristic White (N = 450) Black (N = 358) pa
Pain/discomfort <0.05
I have no pain or discomfort 79 (17.6) 48 (13.5)
I have slight pain or discomfort 151 (33.7) 71 (20.0)
I have moderate pain or discomfort 155 (34.6) 131 (36.9)
I have severe pain or discomfort 51 (11.4) 74 (20.8)
I have extreme pain or discomfort 12 (2.7) 31 (8.7)
Anxiety/depression <0.05
I am not anxious or depressed 158 (35.4) 146 (41.0)
I am slightly anxious or depressed 170 (38.1) 98 (27.5)
I am moderately anxious or depressed 91 (20.4) 65 (18.3)
I am severely anxious or depressed 23 (5.2) 29 (8.1)
I am extremely anxious or depressed 4 (0.9) 18 (5.1)
Visual Analogue Scale (0–100) 74.0 (54.0, 85.0) 75.0 (57.0, 84.0) 0.33
Data are median (interquartile range) or n (%).
ap-Values are based on Pearson chi-square tests for all categorical row variables. p-Values are based on chi-square rank based group
means score statistics for all continuous/ordinal row variables. All tests treat the column variable as nominal.
bHigher score indicates more positive health status.
BMI, body mass index.
Table 4. Baseline Characteristics of Women with a Planned Myomectomy
Characteristic White (N = 526) Black (N = 557) pa
Age (years) 38.0 (33.0, 43.0) 37.0 (33.0, 42.0) 0.07
Insurance <0.05
Private 464 (88.7) 440 (79.4)
Active military 2 (0.4) 10 (1.8)
Other 57 (10.9) 104 (18.8)
BMI (kg/m2) 25.1 (22.2, 30.5) 29.9 (25.7, 36.0) <0.05
Financial toxicity (lower score = worse status) 29.0 (22.0, 35.0) 26.0 (18.4, 33.0) <0.05
Duration of symptoms (years) 2.0 (1.0, 5.0) 4.0 (1.0, 10.0) <0.05
Any bleeding symptoms 409 (77.8) 462 (83.1) <0.05
Menses ‡7 days 267 (50.8) 317 (57.0) <0.05
Heavy menses 378 (71.9) 435 (78.2) <0.05
Bleeding between periods 224 (42.6) 255 (45.9) 0.28
Frequent urination 289 (54.9) 314 (56.5) 0.61
Discomfort during intercourse 199 (37.8) 242 (43.5) 0.06
Pelvic pain requiring meds 174 (33.1) 248 (44.6) <0.05
Pelvic pain not during periods <0.05
Pelvic pain during periods 48 (9.1) 86 (15.5)
No pelvic pain 357 (67.9) 311 (55.9)
Current contraception 390 (74.1) 383 (68.8) 0.05
Previous medical condition (high blood pressure,
diabetes, asthma, thyroid problems, blood clots in legs)
203 (39.1) 242 (43.9) 0.11
Marijuana 51 (9.8) 42 (7.7) 0.23
Any prior UF treatment 73 (14.0) 143 (26.0) <0.05
Regular, predictable menses 368 (71.0) 381 (69.7) 0.62
Number of previous pregnancies <0.05
0 268 (51.5) 211 (38.5)
1 100 (19.2) 117 (21.4)
2 75 (14.4) 91 (16.6)
3 30 (5.8) 51 (9.3)
4 21 (4.0) 37 (6.8)
5 17 (3.3) 19 (3.5)
6 3 (0.6) 10 (1.8)
>6 6 (1.2) 12 (2.2)
Total UF volume (cm3) 158.6 (24.9, 418.2) 152.1 (39.2, 368.4) 0.96
Uterine volume (cm3) 305.6 (137.0, 654.6) 462.2 (225.0, 885.5) <0.05
Number of UFs measured 2.0 (1.0, 3.0) 2.0 (1.0, 4.0) <0.05
Concernb 45.8 (20.0, 76.6) 35.0 (15.0, 65.0) <0.05
Activitiesb 53.6 (35.7, 78.6) 50.0 (28.6, 71.4) <0.05
Energy/moodb 50.0 (32.1, 75.0) 46.4 (25.0, 67.9) <0.05
Controlb 50.0 (30.0, 70.0) 50.0 (25.0, 70.0) 0.58
Self-consciousb 50.0 (25.0, 75.0) 41.7 (16.7, 66.7) <0.05
Sexual Functionb 50.0 (25.0, 75.0) 50.0 (25.0, 87.5) 0.37
Total—sum of 6 subscale scores aboveb 50.0 (33.6, 73.3) 45.7 (28.4, 65.5) <0.05
Symptom severity (lower score indicates
more positive health status)
50.0 (34.4, 67.2) 53.1 (34.4, 75.0) <0.05
Mobility 0.20
I have no problems in walking about 448 (85.2) 441 (79.9)
I have some problems in walking about 47 (8.9) 63 (11.4)
I have moderate problems in walking about 23 (4.4) 32 (5.8)
I have severe problems in walking about 7 (1.3) 13 (2.4)
I am confined to bed 1 (0.2) 3 (0.5)
Self-care 0.32
I have no problems washing or dressing myself 503 (95.6) 524 (94.8)
I have slight problems washing or dressing myself 17 (3.2) 18 (3.3)
I have moderate problems washing or dressing myself 6 (1.1) 7 (1.3)
I have severe problems washing or dressing myself 0 (0.0) 4 (0.7)
I am unable to wash or dress myself 0 (0.0) 0 (0.0)
Usual activities 0.19
I have no problems doing my usual activities 348 (66.3) 382 (69.2)
I have slight problems doing my usual activities 103 (19.6) 94 (17.0)
I have moderate problems doing my usual activities 61 (11.6) 51 (9.2)
I have severe problems doing my usual activities 11 (2.1) 20 (3.6)
I am unable to perform my usual activities 2 (0.4) 5 (0.9)
(continued)
health disparity for this disease. These evidence gaps make
long-term follow-up of cohorts such as COMPARE-UF
critical.
Evidence reports from the Agency for Healthcare Re-
search and Quality have found almost no long-term (>2
years) evidence on comparative effectiveness of UF treat-
ment options and have highlighted the massive knowledge
gaps about UF treatments.26,27 The 2017 report included
only 12 comparative studies of UF procedures, but 6 of
them used hysterectomy as the reference group.28 Only
three studies compared widely available uterine-sparing
procedures with each other, and none included women in
the United States, so results are not generalizable to our
clinical population, where Black women incur the highest
burden of UF. None of these studies had a follow-up time
exceeding 2 years to assess clinical outcomes including
treatment failure.
Nonetheless, most women who have either a hysterec-
tomy or myomectomy to treat their UF will have improved
short-term quality of life. In previous publications from
the COMPARE-UF registry,7 we reported that at 6–12
weeks after treatment, although there were some differences
in specific quality of life subscales, and some influence of
procedure type and route of surgery (open vs. endoscopic),
women who had surgical therapies had decreased symptoms
and improved quality of life.9–11,15 More recently, we re-
ported that overall, both women who had hysterectomy and
those undergoing myomectomy had clinically meaningful
(>10 points) improvement in the UFS-QOL scores 1 year
after the procedure.28
Stronger evidence is available for the long-term effec-
tiveness of UAE.26,27 Based on seven randomized clini-
cal trials studying nearly 8000 participants for up to 10
years following the procedure, there is strong quality
of evidence that UAE results in decreased menstrual
bleeding, volume reduction of UF, and moderate evi-
dence of improved quality of life.26,27 Similar long-term
studies for all uterine-sparing UF treatments and espe-
cially comparative effectiveness studies are critical to
fully determine the effectiveness of all uterine-sparing
procedures.
Limitations of this study include that COMPARE-UF
was designed to assess the comparative effectiveness of
the most common UF treatments rather than to understand
the treatment decision-making process. We did not assess
information on treatment preference, doctor counseling,
or access. The data also focused on the procedure that
was planned, which for only a small number of women
changed during the actual procedure (Appendix Table A3).
The participants are not representative of all women in the
United States, as these participants had access to large health
care institutions, many of which are considered centers of
excellence for UF care, and COMPARE-UF had limited
inclusion of women residing in rural locations. More than
three-quarters of the women in these analyses also had private
insurance. Therefore, by no means are we suggesting that the
experience of the Black women and White women in this
study are representative of the experiences of all Black wo-
men and White women; however, these data do describe the
experience of some Black women and some White women
and should serve as an impetus to improving our under-
standing of the interface between patients, clinical care, and
health systems and providers. Strengths of the study include a
large racially diverse study population from multiple clinical
sites around the country, and the inclusion of a wide range of
UF characteristics abstracted from imaging reports in medical
record data.
Without prevention strategies, UF treatments will
be needed on the present scale over the long term.
Better understanding of the sources of racial differences
in treatment choice, which do not appear to be owing
to UF characteristics or other clinical characteris-
tics, could both impact physician counseling of their pa-
tients as well as inform the development of future UF
treatments. Given the extraordinarily high cumulative
incidence of UF, these changes could lead to improved
quality of life and health for most women in the United
States.
Table 4. (Continued)
Characteristic White (N = 526) Black (N = 557) pa
Pain/discomfort <0.05
I have no pain or discomfort 124 (23.6) 150 (27.1)
I have slight pain or discomfort 210 (39.9) 159 (28.8)
I have moderate pain or discomfort 140 (26.6) 139 (25.1)
I have severe pain or discomfort 41 (7.8) 70 (12.7)
I have extreme pain or discomfort 11 (2.1) 35 (6.3)
Anxiety/depression <0.05
I am not anxious or depressed 173 (33.0) 254 (46.1)
I am slightly anxious or depressed 194 (37.0) 138 (25.0)
I am moderately anxious or depressed 121 (23.1) 104 (18.9)
I am severely anxious or depressed 27 (5.2) 41 (7.4)
I am extremely anxious or depressed 9 (1.7) 14 (2.5)
Visual Analogue Scale (0–100) 76.0 (63.0, 87.0) 79.0 (63.0, 87.0) 0.65
Data are median (interquartile range) or n (%).
ap-Values are based on Pearson chi-square tests for all categorical row variables. p-Values are based on chi-square rank based group
means score statistics for all continuous/ordinal row variables. All tests treat the column variable as nominal.
bHigher score indicates more positive health status.
Table 5. Baseline Characteristics of Women With a Planned Uterine Artery Embolization
Characteristic White (N = 57) Black (N = 196) pa
Age (years) 47.0 (42.0, 49.0) 45.0 (41.0, 47.0) 0.05
Insurance 0.48
Private 45 (80.4) 165 (84.2)
Active military 0 (0.0) 3 (1.5)
Other 11 (19.6) 28 (14.3)
BMI (kg/m2) 27.3 (24.3, 29.9) 31.3 (25.9, 36.9) <0.05
Financial toxicity (lower score = worse status) 27.0 (22.0, 34.0) 27.0 (19.0, 34.0) 0.15
Duration of symptoms (years) 3.0 (1.0, 7.0) 6.0 (2.0, 13.0) <0.05
Any bleeding symptoms 48 (84.2) 179 (91.3) 0.12
Menses ‡7 days 27 (47.4) 126 (64.3) <0.05
Heavy menses 46 (80.7) 164 (83.7) 0.60
Bleeding between periods 21 (36.8) 99 (50.5) 0.07
Frequent urination 40 (70.2) 154 (78.6) 0.19
Discomfort during intercourse 20 (35.1) 87 (44.4) 0.21
Pelvic pain requiring meds 25 (43.9) 99 (50.5) 0.38
Pelvic pain not during periods 0.16
Pelvic pain during periods 3 (5.3) 29 (14.8)
No pelvic pain 32 (56.1) 97 (49.5)
Current contraception 33 (57.9) 129 (65.8) 0.27
Previous medical condition (high blood pressure,
diabetes, asthma, thyroid problems, blood clots in legs)
26 (45.6) 118 (61.1) 0.04
Marijuana 4 (7.1) 8 (4.1) 0.37
Any prior UF treatment 8 (14.0) 38 (19.7) 0.33
Regular, predictable menses 45 (78.9) 99 (51.6) <0.05
Number of previous pregnancies 0.05
0 19 (33.3) 38 (19.7)
1 6 (10.5) 31 (16.1)
2 14 (24.6) 40 (20.7)
3 12 (21.1) 34 (17.6)
4 3 (5.3) 24 (12.4)
5 0 (0.0) 17 (8.8)
6 1 (1.8) 5 (2.6)
> 6 2 (3.5) 4 (2.1)
Total UF volume (cm3) 131.6 (69.4, 346.7) 133.8 (45.0, 307.3) 0.30
Uterine volume (cm3) 507.2 (320.1, 915.6) 542.9 (311.5, 867.8) 0.91
Number of UFs measured 3.0 (1.0, 4.0) 2.0 (1.0, 4.0) 0.90
Concernb 36.6 (13.8, 65.0) 20.0 (5.0, 50.0) <0.05
Activitiesb 46.4 (28.6, 75.0) 39.3 (17.9, 57.1) <0.05
Energy/moodb 46.4 (32.1, 64.3) 35.7 (17.9, 53.6) <0.05
Controlb 45.0 (30.0, 65.0) 40.0 (20.0, 65.0) 0.57
Self-consciousb 33.3 (16.7, 58.3) 25.0 (8.3, 50.0) 0.47
Sexual functionb 50.0 (25.0, 75.0) 37.5 (12.5, 75.0) 0.11
Total (sum of 6 subscale scores above)b 44.0 (31.9, 63.8) 35.8 (19.0, 54.3) <0.05
Symptom severity (lower score indicates
more positive health status)
62.5 (46.9, 71.9) 68.8 (50.0, 81.3) 0.06
Mobility 0.33
I have no problems in walking about 44 (77.2) 146 (74.5)
I have some problems in walking about 11 (19.3) 25 (12.8)
I have moderate problems in walking about 2 (3.5) 17 (8.7)
I have severe problems in walking about 0 (0.0) 6 (3.1)
I am confined to bed 0 (0.0) 2 (1.0)
Self-care 0.45
I have no problems washing or dressing myself 52 (91.2) 184 (93.9)
I have slight problems washing or dressing myself 5 (8.8) 8 (4.1)
I have moderate problems washing or dressing myself 0 (0.0) 3 (1.5)
I have severe problems washing or dressing myself 0 (0.0) 1 (0.5)
I am unable to wash or dress myself 0 (0.0) 0 (0.0)
Usual activities 0.57
I have no problems doing my usual activities 35 (61.4) 122 (62.6)
I have slight problems doing my usual activities 18 (31.6) 45 (23.1)
I have moderate problems doing my usual activities 3 (5.3) 21 (10.8)
I have severe problems doing my usual activities 1 (1.8) 5 (2.6)
I am unable to perform my usual activities 0 (0.0) 2 (1.0)
(continued)
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Table 6. Odds of Black Women Versus White Women Having Uterine-Sparing
Treatment Versus Hysterectomy
OR (95% CI) p
Site-level variance
(95% CI) p
Uterine-sparing treatment is myomectomy or UAE
Race only 1.62 (1.36–1.94) <0.05
Race plus adjustment for site, demographics,
health, SES,a and symptoms
2.72 (1.94–3.81) <0.05 2.54 (0.99–15.32) <0.05
Uterine-sparing treatment is myomectomy
Race only 1.33 (1.11–1.60) <0.05
Race plus adjustment for site, demographics,
health, SES, and symptoms
2.41 (1.63–3.56) <0.05 0.82 (0.36–3.33) <0.05
Uterine-sparing treatment is UAE
Race only 4.32 (3.12–5.99) <0.05
Race plus adjustment for site, demographics,
health, SES, and symptoms
4.24 (2.41–7.46) <0.05 5.84 (2.36–31.06) <0.05
Probability modeled is ‘‘event = uterine-sparing surgery’’; reported ORs are for Black versus White.
aSES variables are insurance type and financial security.
CI, confidence interval; ORs, odds ratios; SES, socioeconomic status.
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Appendix Table A1. Odds of Black Women Versus White Women
Having Uterine-Sparing Treatment Versus Hysterectomy
OR (95% CI) p
Site-level
variance (95% CI) p
Uterine-sparing treatment is myomectomy or UAE or EA or MRgFUS
Race only 1.50 (1.26–1.78) <0.05
Race plus adjustment for site, demographics, health,
SES,a and symptoms
2.26 (1.65–3.09) <0.05 2.43 (0.95–14.51) <0.05
Probability modeled is ‘‘event = uterine-sparing surgery’’; reported ORs are for Black versus White.
aSES variables are insurance type and financial toxicity.
CI, confidence interval; EA, endometrial ablation; MRgFUS, MRI-guided focused ultrasound; ORs, odds ratios; SES, socioeconomic
status; UAE, uterine artery embolization.
Appendix Table A2. Baseline Patient Characteristics by Race
Characteristic White (N = 1033) Black (N = 1111) pa
Age (years) 42.0 (36.0, 47.0)a 41.0 (36.0, 46.0)a <0.05
Insurance <0.05
Private 913 (88.7) 858 (77.4)
Active military 4 (0.4) 15 (1.4)
Other 112 (10.9) 235 (21.2)
BMI (kg/m2) 26.6 (23.0, 31.8) 31.4 (26.7, 37.2) <0.05
Financial toxicity (lower score = worse status) 29.0 (22.0, 36.0) 26.0 (17.0, 32.0) <0.05
Duration of symptoms (years) 3.0 (1.0, 6.0) 5.0 (2.0, 11.0) <0.05
Any bleeding symptoms 832 (80.8) 947 (85.4) <0.05
Menses ‡7 days 548 (53.2) 672 (60.6) <0.05
Heavy menses 768 (74.6) 883 (79.6) <0.05
Bleeding between periods 477 (46.3) 545 (49.1) 0.19
Frequent urination 592 (57.5) 686 (61.9) <0.05
Discomfort during intercourse 412 (40.0) 503 (45.4) <0.05
Pelvic pain requiring meds 408 (39.6) 548 (49.4) <0.05
Pelvic pain not during periods <0.05
Pelvic pain during periods 117 (11.4) 163 (14.7)
No pelvic pain 630 (61.2) 568 (51.2)
Current contraception 736 (71.2) 736 (66.2) <0.05
Previous medical condition (high blood pressure,
diabetes, asthma, thyroid problems, blood clots in legs)
453 (44.5) 577 (52.6) <0.05
Marijuana 82 (8.1) 77 (7.0) <0.05
Any prior treatment 163 (15.9) 264 (24.1) <0.05
Regular, predictable menses 676 (66.3) 648 (59.6) <0.05
Number of pregnancies <0.05
0 407 (39.8) 302 (27.6)
1 168 (16.4) 192 (17.6)
2 187 (18.3) 191 (17.5)
3 123 (12.0) 148 (13.5)
4 62 (6.1) 124 (11.3)
Appendix Table A2. (Continued)
Characteristic White (N = 1033) Black (N = 1111) pa
5 40 (3.9) 66 (6.0)
6 15 (1.5) 31 (2.8)
>6 20 (2.0) 39 (3.6)
Total UF volume (cm3) 140.5 (28.6, 364.8) 147.3 (40.6, 336.7) 0.27
Uterine volume (cm3) 324.2 (159.1, 640.0) 492.5 (255.8, 920.7) <0.05
Number of UFs measured 2.0 (1.0, 3.0) 2.0 (1.0, 4.0) <0.05
Concernb 40.0 (20.0, 71.6) 30.0 (10.0, 55.0) <0.05
Activitiesb 50.0 (28.6, 75.0) 42.9 (21.4, 67.9) <0.05
Energy/moodb 50.0 (28.9, 71.4) 42.9 (21.4, 60.7) <0.05
Controlb 50.0 (30.0, 70.0) 45.0 (25.0, 70.0) <0.05
Self-consciousb 41.7 (16.7, 66.7) 33.3 (8.3, 66.7) <0.05
Sexual functionb 50.0 (25.0, 75.0) 50.0 (12.5, 75.0) 0.27
Total (sum of six subscale scores above)b 47.4 (31.0, 68.1) 40.5 (22.4, 60.3) <0.05
Symptom severity (lower score indicates
more positive health status)
56.3 (37.5, 71.9) 62.5 (40.6, 78.1) <0.05
Mobility <0.05
I have no problems in walking about 852 (82.6) 819 (74.4)
I have some problems in walking about 114 (11.1) 152 (13.8)
I have moderate problems in walking about 51 (4.9) 91 (8.3)
I have severe problems in walking about 13 (1.3) 33 (3.0)
I am confined to bed 1 (0.1) 6 (0.5)
Self-care 0.02
I have no problems washing or dressing myself 978 (95.0) 1029 (93.2)
I have slight problems washing or dressing myself 39 (3.8) 45 (4.1)
I have moderate problems washing or dressing myself 12 (1.2) 21 (1.9)
I have severe problems washing or dressing myself 0 (0.0) 8 (0.7)
I am unable to wash or dress myself 1 (0.1) 1 (0.1)
Usual activities 0.08
I have no problems doing my usual activities 665 (64.5) 708 (64.3)
I have slight problems doing my usual activities 215 (20.9) 215 (19.5)
I have moderate problems doing my usual activities 120 (11.6) 119 (10.8)
I have severe problems doing my usual activities 26 (2.5) 45 (4.1)
I am unable to perform my usual activities 5 (0.5) 14 (1.3)
Pain/discomfort <0.05
I have no pain or discomfort 213 (20.7) 229 (20.7)
I have slight pain or discomfort 387 (37.5) 288 (26.1)
I have moderate pain or discomfort 315 (30.6) 324 (29.3)
I have severe pain or discomfort 93 (9.0) 179 (16.2)
I have extreme pain or discomfort 23 (2.2) 84 (7.6)
Anxiety/depression <0.05
I am not anxious or depressed 353 (34.4) 475 (43.1)
I am slightly anxious or depressed 388 (37.8) 300 (27.2)
I am moderately anxious or depressed 222 (21.6) 205 (18.6)
I am severely anxious or depressed 50 (4.9) 85 (7.7)
I am extremely anxious or depressed 14 (1.4) 37 (3.4)
Visual analog scale (0–100) 75.0 (60.0, 85.0) 75.0 (60.0, 86.0) 0.17
Data are given s median (interquartile range) or n (%).
ap-Values are based on Pearson chi-square tests for all categorical row variables. p-Values are based on chi-square rank-based group means
score statistics for all continuous/ordinal row variables. This is equivalent to Wilcoxon tests. All tests treat the column variable as nominal.
bHigher score indicates more positive health status.
BMI, body mass index; UF, uterine fibroid.
Appendix Table A3. Planned Treatment Versus Completed Treatment
Actual treatment performed
Unknown Myo Hyst UAE EA RFA IUD
Planned treatment
Myo 19 1042 18 0 4 0 0
Hyst 8 5 795 0 0 0 0
UAE 34 0 0 219 0 0 0
Values in bold are concordant planned and completed treatments.
Planned treatment is based on participant report, and completed treatment is from medical chart review.
Hyst, hysterectomy; IUD, intrauterine device; Myo, myomectomy; RFA, radiofrequency ablation.
